<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 26, 1996
----------------------
NU-TECH BIO-MED, INC.
- -------------------------------------------------------------------------------
(Exact Name of Registrant as specified in charter)
Delaware 0-11772 25-1411971
(State or other jurisdic- (Commission (IRS Employer
tion of incorporation) File Number) Identification No.)
55 Access Road, Warwick, Rhode Island 02886
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (401) 732-6520
-----------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE> 2
ITEM 5. OTHER EVENTS.
Nu-Tech Bio-Med, Inc. (the "Company") has recently received notice from
the State of Rhode Island that its wholly-owned subsidiary, Analytical
Biosystems Corporation, had received approval, effective May 21, 1996, from the
State of Rhode Island Department of Health that its clinical laboratory license
had been expanded to include laboratory testing for routine chemistry,
histopathology and cytology and that the expanded testing approvals had been
added to the CLIA database.
The expansion of the clinical license will allow the Company to provide
additional services to health care providers and to bill third party insurance
carriers under existing CPT codes. Management believes that these changes to its
clinical license, and the resultant ability to utilize existing CPT codes, will
increase the Company's reimbursement of its testing procedures.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
-----------------------------
J. Marvin Feigenbaum
Chairman of the Board,
President, Chief Executive
and Chief Financial Officer
Dated: June 26, 1996
2
